Isis cites promising results on new drug Nov 18, 2009
Isis Pharmaceuticals reported encouraging results yesterday with a cholesterol-lowering drug but also extended the timeline for getting it on the market. The Carlsbad company, which is developing the drug with the Massachusetts company Genzyme, said it cut cholesterol 25 percent in a study of patients with a rare genetic disorder that sends cholesterol levels sky-high. (San Diego Union-Tribune)
Treatment Neutralizes Muscular Dystrophy in Mice Jul 18, 2009
Several companies, including Isis Pharmaceuticals, are developing drugs using this approach. Thornton said unlike many inherited diseases in which faulty genes make faulty or missing proteins, myotonic dystrophy makes a toxic form of ribonucleic acid or RNA, which carries genetic instructions for making proteins. (MEDLINEplus)
Gene Inhibition May Help Normalize Type 2 Diabetes Jun 20, 2009
L. Horvath and Qian Gao of Yale School of Medicine; Xing Xian Yu, Susan F. Murray, Sanjay Bhanot and Brett P. Monia of Isis Pharmaceuticals in Carlsbad, CA.. The work above was funded in part by the Yale Clinical and Translational Science Award (CTSA) grant from the National Center for Research Resources at the National Institutes of Health. (Science Daily)
BIOTECH: Isis drug meets goal, stock falls on safety worries May 21, 2009
CARLSBAD ---- Shares of Isis Pharmaceuticals Inc. fell 10 percent Wednesday after it reported what observers viewed as mixed results of its flagship cholesterol-lowering drug. Isis closed at 13. (North County Times)
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427 May 15, 2009
OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. (PR Newswire)
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer Apr 28, 2009
Having evaluated both of these endpoints in our Phase 2 trials, we are well positioned to re-evaluate each of these endpoints in larger Phase 3 registration trials. " "The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the basis of our OGX-011 development program for advanced prostate cancer," added Cormack. "Although we observed a positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA response has not been shown to... (Canada Newswire)
Missing Link Between Fructose, Insulin Resistance Found Mar 10, 2009
The researchers include Yoshio Nagai, Yale University School of Medicine, New Haven, CT , Howard Hughes Medical InstituteShin Yonemitsu, Yale University School of Medicine, New Haven, CT , Howard Hughes Medical Institute; Derek M. Erion, Yale University School of Medicine, New Haven, CT, Howard Hughes Medical Institute; Takanori Iwasaki, Yale University School of Medicine, New Haven, CT; Romana Stark, Yale University School of Medicine, New Haven, CT; Dirk Weismann, Yale University School of... (Science Daily)
BIOTECH: Regulus raises $20 million Mar 5, 2009
The money came equally from Isis Pharmaceuticals Inc., based in Carlsbad, and Alnylam Pharmaceuticals Inc., of Cambridge, Mass. The two companies established Regulus as a joint venture in September 2007 to research and develop drugs based on small segments of RNA called "microRNA.". (North County Times)
BIOTECH: Isis posts $8.7M loss Feb 26, 2009
CARLSBAD ---- Isis Pharmaceuticals Inc. lost 8. 7 million, or 9 cents per share, in the quarter ended Dec. 31. (North County Times)
